Man (60s) killed in Wexford crash and gardaí arrest man (40s) at scene; man (50s) killed in separate crash in Roscommon - The Irish Independent

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN) – Novartis

October 17, 2025

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN) NovartisNovartis advances IgAN efforts with phase 3 win for Fabhalta, plots FDA filing for full approval Fierce PharmaNovartis’ Fabhalta slows progression of rare kidney disease in trial ReutersNovartis confirms drug’s benefits in rare kidney disease as competitors loom BioPharma DiveAPPEAR-C3G: Iptacopan Shows Proteinuria Reduction, eGFR Benefits in C3G HCPLive